Oncolytics Biotech Inc ONCY

Primary Symbol: T.ONC

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > Options

<< Previous

Bullboard Posts

Next >>

Comment by lonc17on Dec 09, 2023 6:58pm

122 Views

Post# 35776542

RE:RE:Options

Okay, sorry, I have confirmed that those options are all expired, converted, etc. upon departure from the company (even though the record does not show this on SEDI).

Hence, the only two of interest for Monday will be KL and MC, as they are (unfortunately) still with the company.

<< Previous

Bullboard Posts

Next >>

10 common investing mistakes to avoid